Merck KGaA: Merck announced that it had signed an agreement to acquire AmpTec, a leading provider of high-quality RNA and mRNA for research and commercial applications. The acquisition will strengthen Merck's capabilities in the field of mRNA-based therapeutics and vaccines.
Roche Holdings Inc.: Roche announced that it had received approval from the US Food and Drug Administration (FDA) for its recombinant protein Hemlibra, for the treatment of hemophilia A in patients without factor VIII inhibitors. Hemlibra is a bispecific antibody designed to bring together factors IXa and X, which are needed to activate the natural coagulation cascade and restore the blood clotting process.
Author Credits: Radhika Gupta, Shivam Bhutani